Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Respules Market?

The market for gastroparesis drugs has seen substantial growth in the past few years. It’s expected to increase from $5.39 billion in 2024 to $5.7 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. Reasons for the growth in the historical period include the side effects associated with current treatments, research into gastrointestinal motility, clinical necessity, support from patient advocacy groups, and assistance from regulatory bodies.

In the forthcoming years, the market size for gastroparesis drugs is anticipated to experience robust expansion, set to reach “$7.04 billion by 2029“, progressing at a compound annual growth rate (CAGR) of “5.4%“. The predicted growth during this estimated period can be credited to factors such as the surging prevalence of diabetes, an aging demographic, heightened awareness and diagnosis procedures, augmentation in healthcare spending as well as governmental and private-sector investment. Foreseen trends within this period comprise advancements in the field of gastroenterology, progress in diagnostic methodologies, technological innovations, funding for research, and cooperative research initiatives.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Factor Is Shaping The Future Of The Respules Market?

An increase in respiratory ailments is anticipated to spur the respules market’s expansion. These respiratory diseases include lung conditions and sicknesses such as tuberculosis, lung cancer, pulmonary hypertension, mesothelioma, cystic fibrosis, emphysema, and asthma. Respules are used to manage a variety of respiratory diseases, such as bronchial asthma, emphysema, spasmodic stenosis, and irregular bronchial mucus production. For instance, the Australian Bureau of Statistics, a governmental agency in Australia, reported in December 2023 that in 2022, 2.5% of the populace (638,100 individuals) suffered from COPD, showing similar prevalence amongst males (2.4%) and females (2.6%). Daily smokers were significantly more prone to COPD (8.1%) in comparison to former smokers (4.4%) and those who had never smoked (1.6%). Consequently, the increasing prevalence of respiratory disorders is fueling the expansion of the respules market.

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Which Emerging Trends And Strategic Shifts Are Shaping The Respules Market?

Leading enterprises within the realm of the gastroparesis drugs market are pivoting towards the launch of inventive drugs like Gimoti (metoclopramide) nasal spray to establish an advantageous position within the industry. Gimoti (metoclopramide) nasal spray functions as therapeutic medication for gastroparesis symptoms in adults by boosting stomach clearing through amplified gastrointestinal mobility. This drug bypasses the gastrointestinal passage and infiltrates into the bloodstream directly via nasal mucosa. Evoke Pharma Inc., an American pharmaceutical firm, proclaimed in April 2022 that the U.S. Food and Drug Administration (FDA) allotted fresh drug product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity under the Hatch-Waxman Act bestows Evoke the exclusive privilege to market the drug for a period of three years from the initial approval date, protecting it from competition by generics.

Which Companies Hold The Largest Market Share In The Respules Sector?

Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

How Does Regional Performance Compare Across The Respules Industry?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model